Department of breast surgery, Gentofte Hospital
Gentofte Municipality, Denmark
NCT Number: NCT05760755
This pilot study investigates the acceptability and feasibility of 'Stick Together', a self-guided online intervention, for younger women with breast cancer and their cohabiting partners.
Looking for future studies?
Notify Me25 year–49 year
Female
Interventional
Not applicable
Gentofte Municipality, Denmark
This one-arm feasibility study pilots the 'Stick Together' intervention among 20 women newly diagnosed with breast cancer at age 25-49 and their cohabiting partners. The intervention aims to strengthen couples' positive dyadic coping and communication, as well as participants mental health and quality of life, as well as quality of life of underage children.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
(patients):
Inclusion criteria
(partners):
Exclusion criteria
(both patients and partners):
The intervention consists of 12 online modules, completed flexibly during and immediately after primary cancer treatment. The intervention contains interviews with other couples, psychoeducational information, and interactive exercises on themes such as dyadic coping and communication, being diagnosed at a young age, fertility and children, and life after treatment.
Time frame: baseline
Percentage of eligible participants consenting to participate
Time frame: Post-intervention follow-up (7-9 months post diagnosis)
Percentage of participants satisfied with the intervention
Time frame: Post-intervention (7-9 months post diagnosis)
Percentage of participants completing the intervention (65% completion)
Time frame: Baseline, after intervention completion (average 8 months after diagnosis)
Score on supportive dyadic coping (min 5, max 25), as measured by the Dyadic coping inventory subscale. Higher scores indicate better outcome.
Time frame: Baseline, after intervention completion (average 8 months after diagnosis)
Score on delegated dyadic coping (min 2, max 10), as measured by the Dyadic coping inventory subscale. Higher scores indicate better outcome.
Time frame: Baseline, after intervention completion (average 8 months after diagnosis)
Score on negative dyadic coping (min 4, max 20), as measured by the Dyadic coping inventory subscale. Higher scores indicate worse outcome.
Time frame: Baseline, after intervention completion (average 8 months after diagnosis)
Score on stress communication (min 4, max 20), as measured by the Dyadic coping inventory subscale. Higher scores indicate better outcome.
Time frame: Baseline, after intervention completion (average 8 months after diagnosis)
Score on satisfaction with dyadic coping (min 2, max 10), as measured by the Dyadic coping inventory subscale. Higher scores indicate better outcome.
Time frame: Baseline, after intervention completion (average 8 months after diagnosis)
Score on joint dyadic coping (min 5, max 25), as measured by the Dyadic coping inventory subscale. Higher scores indicate better outcome.
Time frame: Baseline, after intervention completion (average 8 months after diagnosis)
Score on perceived stress (min 0, max 16), as measured by the Perceived Stress Scale. Higher scores indicate worse outcome.
Time frame: Baseline, after intervention completion (average 8 months after diagnosis)
Score on anxiety symptoms (min 0, max 21), as measured by the Generalized anxiety scale-7. Higher scores indicate worse outcome.
Time frame: Baseline, after intervention completion (average 8 months after diagnosis)
Score on depression symptoms (min 0, max 27), as measured by the Patient Health Questionnaire-9. Higher scores indicate worse outcome.
Time frame: Baseline, after intervention completion (average 8 months after diagnosis)
Score on protective buffering (min 8, max 40), as measured by the Ways of Giving Support-questionnaire subscale. Higher scores indicate worse outcome.
Time frame: Baseline, after intervention completion (average 8 months after diagnosis)
Score on active engagement (min 5, max 25), as measured by the Ways of Giving Support-questionnaire subscale. Higher scores indicate better outcome.
Time frame: Baseline, after intervention completion (average 8 months after diagnosis)
Score on overprotection (min 6, max 30), as measured by the Ways of Giving Support-questionnaire subscale. Higher scores indicate worse outcome.
Time frame: Baseline, after intervention completion (average 8 months after diagnosis)
Score on psychological quality of life (min 0, max 100), as measured by the World Health Organization Quality of Life Brief Version subscale (WHOQOL-BREF). Higher scores indicate better outcome.
Time frame: Baseline, after intervention completion (average 8 months after diagnosis)
Score on physical quality of life (min 0, max 100), as measured by the World Health Organization Quality of Life Brief Version scubscale (WHOQOL-BREF). Higher scores indicate better outcome.
Time frame: Baseline, after intervention completion (average 8 months after diagnosis)
Score on social quality of life (min 0, max 100), as measured by the World Health Organization Quality of Life Brief Version subscale (WHOQOL-BREF). Higher scores indicate better outcome.
Time frame: Baseline, after intervention completion (average 8 months after diagnosis)
Total mean score on quality of life (min 0, max 100), as measured by the Pediatric Quality of LIfe inventory (PEDSQL). Higher scores indicate better outcome.
Rigshospitalet, Denmark
Other
Stick Together - a Dyadic Web-intervention for Younger Patients with Breast Cancer and Their Partners
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06701019
Breast Cancer Female
Nottingham, Nottinghamshire, United Kingdom
View Trial DetailsNCT06636591
Breast Cancer Female, HER2-negative Breast Cancer
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT05376644
Breast Cancer Female, Breast Diseases
Tomsk, Russia
View Trial DetailsNCT05203497
Breast Cancer Female, Breast Diseases
Tomsk, Russia
View Trial Details